


Dr. Surendra Chavan, M. Sc. Ph.D.



Dr. Surendra Chavan **an alumnus of Cancer Research Institute** (completed PhD in 1993) has more than 25 years of biotechnology experience of which the last 12 years have been dedicated to the development of bio-therapeutic molecules including fusion proteins, and chimeric and humanized monoclonal antibodies for treatment of cancer and autoimmunity diseases. Dr. Chavan has over 12 years of global drug development experience covering preclinical, and early stage clinical development, clinical operations, regulatory and safety functions. During this period, Dr. Chavan has held several positions of increasing responsibility and has successfully led drug development research programs at Celtaxsys, Inc (Atlanta, USA), Forest Life Sciences (San Diego, California, USA) and Bioquant, (San Diego California, USA) which resulted in 10 US patents. Dr. Chavan's **expertise in Clinical Immunology has allowed him to successfully manage global teams** during the development/validation phase of several immunology- and cell biology-based assays for preclinical and clinical evaluation of novel bio-drugs. In academia, Dr. Chavan was the Clinical Director for the Pediatric HIV Immunology Laboratory at the North Shore University Hospital in New York.

Dr. Chavan holds a diverse repertoire of experiences in biomedical, translational and clinical research. He is **one of the founders of the real time fluorescent reverse transcriptase assay** that forms the basis of today's real time PCR technology platform. During his first postdoctoral training at Memorial Sloan-Kettering Cancer Center in NY, he invented a novel method for purification of the HIV reverse transcriptase enzyme. Throughout his career he has developed several preclinical animal models, real time PCR, and flow cytometry protocols for research and clinical use. He has received several awards for his scientific contributions including the **Henry Christian Award from American Federation for Medical Research Foundation, USA** for his research on **HIV-protease inhibitor "Indinavir"**. His true asset is that his **research experience has evolved in academic as well as regulated GLP compliant industrial settings.**

Dr. Chavan earned his Ph.D. in Biochemistry (with expertise in Cancer Chemotherapy research) from the prestigious "The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), formerly known as Cancer Research Institute", Mumbai, India. ACTREC is one of the finest and largest cancer research institutes in South-East Asia. Prior to that he obtained his master degree in Biotechnology from the world famous "Indian Institute of Technology" Mumbai, India. Dr. Chavan has over 50 publications in peer-reviewed journals and has been an important contributor to various scientific meetings throughout North America.